Oddo BHF Asset Management Sas Buys Shares of 73,091 Twist Bioscience Co. (NASDAQ:TWST)

Oddo BHF Asset Management Sas acquired a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,091 shares of the company's stock, valued at approximately $3,302,000. Oddo BHF Asset Management Sas owned about 0.12% of Twist Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience during the 3rd quarter worth about $34,000. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $43,000. Blue Trust Inc. boosted its position in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after purchasing an additional 1,136 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience in the second quarter valued at approximately $61,000.

Insider Activity

In related news, insider Dennis Cho sold 659 shares of the firm's stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the transaction, the insider now owns 94,481 shares of the company's stock, valued at $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Emily M. Leproust sold 14,334 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the transaction, the chief executive officer now directly owns 589,552 shares in the company, valued at $26,294,019.20. This represents a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,787 shares of company stock valued at $4,584,508. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Stock Performance

Shares of TWST stock traded up $0.11 during mid-day trading on Friday, hitting $47.50. 811,693 shares of the stock were exchanged, compared to its average volume of 940,837. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -13.16 and a beta of 1.82. The stock's fifty day simple moving average is $44.85 and its two-hundred day simple moving average is $46.60.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research reports. TD Cowen reaffirmed a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 19th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday. They issued an "outperform" rating and a $60.00 price objective on the stock. Leerink Partners boosted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research note on Thursday, October 17th. Finally, Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $51.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.